Pharma & Biotech
-
Langhorne’s Nexgel Transforms Near Disaster into ‘Three-Team Trade’ Acquisition
Despite the withdrawal of an investor, Langhorne-based Nexgel successfully finalized its acquisition of Celularity’s regenerative biomaterial products, a deal that is expected to nearly triple the company’s annual revenue to around $35 million, writes John George for the Philadelphia Business Journal. CEO Adam Levy said that the Bucks County wound care manufacturer finalized the deal…
-
Newtown-Based Traws Pharma Shares Full-Year Results, Clinical Progress
Last week, Newtown-based Traws Pharma reported its full-year 2025 financial results and provided updates on its influenza and COVID drug programs. The company, which develops novel therapies to target critical threats to human health from respiratory viral diseases, also reported the completion of a private investment in public equity financing of up to $60 million…
-
Two Life Sciences Companies with Doylestown Connections Raise $119M
Aprea Therapeutics and Pinnacle Medicines, two life sciences companies with connections to Doylestown, have raised a combined $119 million from investors, writes John George for the Philadelphia Business Journal. Life sciences companies in the Philadelphia region have raised over $850 million through venture capital deals and follow-on stock offerings. Aprea Therapeutics, which is headquartered in the Pennsylvania Biotechnology Center…
-
Conshohocken’s Cencora Prepares for Leadership Change This Summer
Conshohocken’s Cencora is preparing for a major leadership transition as executive vice president and chief financial officer James Cleary plans to step down, writes Sydney Halleman for HealthCareDive. The company said Cleary will officially step down on June 30, but will remain with Cencora through the end of the year in an advisory capacity as…
-
Malvern’s Neuronetics Announces New CEO as 2025 Revenue Nearly Doubles to $149M
Right when it reported a 99 percent revenue jump, Malvern-based Neuronetics appointed Dan Reuvers, a medical device industry veteran, as its next CEO, writes John George for the Philadelphia Business Journal. Reuvers will assume the top role at the medical technology company on March 23, succeeding Keith Sullivan, whose tenure started in July 2020. Sullivan revealed in November that he will be retiring…
-
Doylestown Biotech Targets Neonatal Lung Disease With Vitamin A Therapies
Doylestown-based Advent Therapeutics has been working on vitamin A therapy aimed at preventing chronic lung disease in premature infants, a condition with few modern treatments, writes Holly Quinn for Technical.ly. The company focuses particularly on bronchopulmonary dysplasia, a chronic lung disease affecting extremely premature infants. One form of the treatment would be administered through an…
-
Warminster-Founded Arbutus Biopharma to Receive $190M in Moderna Settlement
Four years after suing Moderna over its Covid-19 vaccine, Arbutus Biopharma, which was formerly headquartered in Warminster, has secured a $190 million share of a $950 million settlement, writes John George for the Philadelphia Business Journal. Filed together with Genevant Sciences in early 2022, the patent infringement lawsuit claimed that Moderna’s vaccine violated several U.S.…
-
Bucks County Biotech Leader Gregory Krug Honored With 2025 ICON Award
Gregory Krug, co-founder of Lampire Biological Laboratories in Doylestown, has been recognized with the prestigious 2025 ICON Honors Award, writes Walt Frank for Altoona Mirror. Presented to business leaders aged 60 and older, the award recognizes exceptional leadership, professional accomplishment, and significant impact in the greater Lehigh Valley region. The 72-year-old Krug has played a…
-
Montco Vaccine Maker Bets Its Data May Be Worth as Much as Its Science
Ambler’s MBF Therapeutics believes the data behind its vaccines could become just as valuable as the vaccines themselves, writes Holly Quinn for Technical.ly. The company has spent more than a decade developing a non-viral vaccine platform for animal health. According to CEO and cofounder Tom Tillett, MBF is exploring whether its detailed immune-response data could…
-
Madrigal’s Rezdiffra Nears Blockbuster Status With $958M in First Full Year on Market
In its first full year on the market, West Conshohocken-based Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly got to blockbuster status, bringing in $958.4 million in 2025, writes John George for the Philadelphia Business Journal. The treatment for MASH, a progressive liver disease metabolic dysfunction-associated steatohepatitis, marked the company’s largest advancement since being founded in 2011.…
-
Johnson & Johnson Expands its Montco Footprint with $1B Investment
Johnson & Johnson is making another major bet on Montgomery County, writes Harold Brubaker for The Philadelphia Inquirer. The pharmaceutical giant announced plans to invest more than $1 billion to build a new cell therapy manufacturing facility in Lower Gwynedd Township near its Spring House campus. The plant is expected to create about 500 jobs…
-
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor
Doylestown-based Aprea Therapeutics has named Eugene Kennedy, MD, as chief medical advisor, adding a seasoned leader in oncology drug development to its executive team. Aprea is a clinical-stage biopharmaceutical company advancing innovative therapies targeting cancer-specific vulnerabilities while minimizing damage to healthy cells. Kennedy joins after early clinical proof-of-concept was demonstrated for the WEE1 inhibitor APR-1051…
-
Eli Lilly to Build $3.5B Weight-Loss Drug Plant in Upper Macungie
Eli Lilly plans to build a $3.5 billion pharmaceutical plant in Upper Macungie Township, just north of Montgomery County, for its next-generation weight-loss medicines, writes Harold Brubaker for The Philadelphia Inquirer. The selection of the Lehigh Valley for one of Eli Lilly’s four new U.S. factories represents a significant win for Pennsylvania as it competes…
-
Conshohocken-based Cencora’s New Partnership Speeds Rare Disease Treatment to Market
Conshohocken’s Cencora partnered with Curant Rare to help rare disease treatments reach patients faster and more smoothly, the companies announced in a press release. Curant Rare announced a strategic collaboration with Cencora to support pharmaceutical companies bringing rare disease therapies to market. Rare disease drugs often face added hurdles, including complex regulations and limited patient…
-
Plymouth Meeting Pharmaceutical Company Eyes $1B Milestone
Harmony Biosciences says its flagship narcolepsy drug is on track to hit a major milestone, writes John George for The Philadelphia Business Journal. The Plymouth Meeting business expects Wakix to surpass $1 billion in annual revenue this year. The drug treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. It generated $868 million in…
-
New Hope’s Orchestra BioMed Set to Receive $21M from Vivasure Sale
Orchestra BioMed, based in New Hope, is set to receive as much as $21 million in cash proceeds tied to Haemonetics Corporation’s acquisition of Ireland-based Vivasure. Before the transaction closed on Jan. 9, 2026, Vivasure was a strategic holding of Orchestra BioMed. The Bucks County biomedical innovation company, which specializes in accelerating high-impact technologies to…
-
National Institutes of Health Director Visits Doylestown Biotech Campus
On Jan. 5, the Hepatitis B Foundation, Baruch S. Blumberg Institute, and Pennsylvania Biotechnology Center (PABC) welcomed National Institutes of Health Director Jay Bhattacharya, MD, PhD to their Doylestown campus. The nonprofits had the opportunity to highlight their academic programs, innovations, and collaborative research that support public health and advance biomedical discovery. The visit was organized by U.S. Rep. Brian…
-
Merck Leads the Pharmaceutical Pack with Net-Zero Strategy
Pharmaceutical giant Merck is accelerating its push toward net-zero emissions, renewable energy and long-term environmental stewardship, writes Chloe Williment for Sustainability Magazine. Merck has committed to reducing energy demand while rapidly expanding its use of renewable power, particularly across energy-intensive healthcare manufacturing. Over the past five years, the company has secured 209 megawatts of renewable…
Founding Partners
Advertisement
Affiliate Partners
